Table 4

Correlations of best Snellen corrected visual acuity (BCVA), mean deviation (MD) and central foveal thickness (CFT) with disease duration in patients with different types of USH2A mutations

M+MM+SNFOSNFO+SNFO
rP valuerP valuerP value
BCVA versus duration−0.574<0.001−0.2840.001−0.528<0.001
 −≤10 years−0.4330.025−0.4440.012−0.6840.031
 −10 to 20 years−0.1520.338−0.3390.045−0.1320.327
 −>20 years−0.3840.005−0.0020.493−0.0380.436
MD versus duration−0.3150.027−0.2450.024−0.2390.155
 −≤10 years−0.3000.171−0.0300.454−0.1200.411
 −10 to 20 years−0.8940.053−0.3520.108−0.8940.053
 −>20 years−0.5250.006−0.2200.106−0.3030.197
CFT versus duration−0.1770.154−0.455<0.001−0.010.481
 −≤10 years−0.773−0.004−0.040.437−0.8940.053
 −10 to 20 years−0.0510.452−0.0130.480−0.0490.446
 −>20 years−0.6730.002−0.5400.007−0.2780.219
  • BCVA, best Snellen corrected visual acuity; CFT, center foveal thickness; M, missense; MD, mean deviation; RP, retinitis pigmentosa; SNFO, splice-site, nonsense, frameshift, or others (readthrough, gross deletions and small indels); USH2, Usher syndrome type IIa.